{"id":"W1962272706","doi":"10.1093/eurheartj/ehv370","title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","year":2015,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":534,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Kowa Company; Esperion Therapeutics; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Servier; Amgen; Pfizer; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Alirocumab; Medicine; Placebo; Discontinuation; Internal medicine; PCSK9; Gastroenterology; Clinical endpoint; Adverse effect; Randomized controlled trial; Endocrinology; Cholesterol; Apolipoprotein B; Lipoprotein; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001512737,0.000847615,0.002138247,0.0002796529,0.0003799959,0.0004837335,0.0003610353,0.0008906709,0.002575902],"category_scores_gemma":[0.001293124,0.0004766226,0.001882957,0.000179764,0.000455488,0.0005308259,0.0003760506,0.0008439163,0.0002207532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008370058,"about_ca_system_score_gemma":0.0006514796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002096303,"about_ca_topic_score_gemma":0.005307657,"domain_scores_codex":[0.9994304,0.0002495488,0.00005882591,0.0001015266,0.00006419024,0.00009541478],"domain_scores_gemma":[0.9989831,0.0001787879,0.0003109679,0.00007239317,0.00007134883,0.0003834931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9066147,0.01056736,0.0186404,0.0008556083,0.002746993,0.0001929765,0.0002097554,0.0004316612,0.008814206,0.00006365959,0.001052425,0.04981019],"study_design_scores_gemma":[0.4835664,0.3549588,0.1532937,0.00009817882,0.003350399,0.0002858869,0.0001279353,0.0006160692,0.001904331,0.00007786066,0.001645493,0.00007485665],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969591,0.001742376,0.0001150438,0.00009014834,0.00003129179,0.0002487813,0.0002961256,0.00001252706,0.0005046691],"genre_scores_gemma":[0.9965712,0.0007309302,0.0005307475,0.0002611059,0.00008630889,0.0003501284,0.0005706332,0.000003801186,0.0008950494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002575902,"threshold_uncertainty_score":0.008617282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04032491007896476,"score_gpt":0.2640132499836305,"score_spread":0.2236883399046657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}